As menopause approaches, these symptoms can progressively worsen
Among the most pressing concerns is the emergence of nutrient insufficiencies, driven not by malabsorption per se, but by profound reductions in energy intake and food variety
This corresponds with sustained appetite reduction and improved food choices, as the medication makes high-calorie foods less appealing
Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in clinical trials Tirzepatide 15 mg (Zepbound): ~21% body weight loss at 72 weeks in clinical trials Real-world data shows lower results: Cleveland Clinic research from 2025 found average weight loss of 7.7% with semaglutide and 12.4% with tirzepatide at one year in routine clinical practice
Geniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of alzheimers disease
I started Noom almost 5 weeks ago, a SHE Media seller tells me
